How was the deal introduced?

Chris Yates, CEO, was invited to one of Mercia’s NED networking events hosted in Leeds. One of our Platform Team was aware that the company was looking for investment and facilitated an introduction to the Investment Manager.

What did the company plan to use the initial funds for?

The company is using Mercia’s investment to fund the operational development required to support the growth in its contract services business. The company has seen strong growth in contract development and expects to be able to transfer three new tests from an R&D phase to a commercialised, contract manufacturing phase during 2019.

Funding will be used specifically to increase headcount in the operational team and to expand the company’s York production facility to allow fulfilment of these manufacturing contracts as well as bolstering the company’s sales function.

What progress has the company made since the first investment?

The company has secured an additional four rapid test development contracts in the first four months of 2019, including a sizeable contract with a large pharmaceutical company in the fast-growing area of personalised medicine and company diagnostics. The Company is expanding production operations at its site in York to service increasing manufacturing volumes. Mercia is also offering further operational support as the business continues to plan for the growth of its operations.

The Mercia Effect

What have we been able to do for this company as a result of our involvement?

Mercia’s Investment Director introduced a potential NED who is a well-known industry veteran, and the team are delighted to be securing his services.  In addition, Mercia introduced a new business development director with significant industry knowledge, enabling the company to resource for additional growth.

“We found the Mercia investment process to be straightforward and succinct, with due diligence taking only a few months after we agreed terms. Post-deal Mercia has helped with useful introductions, including our new business development director and potential NED candidates.”Chris Yates, Abingdon Health

Business Description

Faradion is a developer, licensor and supplier of sodium-ion battery materials that can offer higher performance, improved safety and lower cost when compared to lithium-ion batteries.

Rationale for Investment

Commercialising its sodium-ion battery technology by working with licensees and manufacturers to address the global demand for stationary energy storage and electric mobility solutions.

www.faradion.co.uk

Business Description

Intechnica is a developer of Netacea, a SaaS platform for web traffic and bot management as well as a leading provider of IT consulting services to improve web performance and resilience.

Rationale for Investment

Building on a stable consulting business and client base, the opportunity to build a SaaS business by providing intelligent web traffic, bot management, virtual waiting rooms solutions.

www.intechnica.com